Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

May 15, 2025

Conditions

Acute Lymphoblastic LeukemiaNon-hodgkin Lymphoma

Interventions

DRUG

Metabolically Armed CD19 CAR-T cells

Each subject receive metabolically armed CD19 CAR- T cells by intravenous infusion.

Trial Locations (1)

RECRUITING

Anhui Provincial Hospital, Hefei